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PURPOSE. To longitudinally characterize retinal structure and function in achromatopsia
(ACHM) in preparation for clinical gene therapy trials.
METHODS. Thirty-eight molecularly confirmed ACHM subjects underwent serial assessments,
including spectral domain optical coherence tomography (SD-OCT), microperimetry, and
fundus autofluorescence (FAF). Foveal structure on SD-OCT was graded and compared for
evidence of progression, along with serial measurements of foveal total retinal thickness
(FTRT) and outer nuclear layer (ONL) thickness. Fundus autofluorescence patterns were
characterized and compared over time.
RESULTS. Mean follow-up was 19.5 months (age range at baseline, 6–52 years). Only 2 (5%) of
37 subjects demonstrated change in serial foveal SD-OCT scans. There was no statistically
significant change over time in FTRT (P ¼ 0.83), ONL thickness (P ¼ 0.27), hyporeflective
zone diameter (P ¼ 0.42), visual acuity (P ¼ 0.89), contrast sensitivity (P ¼ 0.22), mean
retinal sensitivity (P ¼ 0.84), and fixation stability (P ¼ 0.58). Three distinct FAF patterns
were observed (n ¼ 30): central increased FAF (n ¼ 4), normal FAF (n ¼ 11), and well-
demarcated reduced FAF (n ¼ 15); with the latter group displaying a slow increase in the area
of reduced FAF of 0.03 mm2 over 19.3 months (P ¼ 0.002).
CONCLUSIONS. Previously published cross-sectional studies have described conflicting findings
with respect to the age-dependency of progression. This study, which constitutes the largest
and longest prospective longitudinal study of ACHM to date, suggests that although ACHM
may be progressive, any such progression is slow and subtle in most patients, and does not
correlate with age or genotype. We also describe the first serial assessment of FAF, which is
highly variable between individuals, even of similar age and genotype.
Keywords: achromatopsia, gene therapy, optical coherence tomography, retinal dystrophy,
retinal degeneration
Achromatopsia (ACHM) is an autosomal recessive conedysfunction syndrome affecting approximately 1 in
30,000 people, and characterized by the presentation in
infancy of pendular nystagmus, poor visual acuity, and
photophobia.1 Electroretinography (ERG) demonstrates absent
cone responses and normal or near-normal rod responses,2,3
with psychophysical testing revealing normal rod function but
absent or severely reduced cone function.4 To date, five genes
have been found to be associated with ACHM, all encoding
components of the cone-specific phototransduction cascade.
The two most common of these are CNGA35 and CNGB3,6
encoding the a- and b-subunits of the cGMP-gated cation
channel respectively, and together account for approximately
70% of cases.7 Disease-causing sequence variants also have
been identified in GNAT2,8 PDE6C,9 and PDE6H,10 each
responsible for fewer than 2% of cases.8–10
Several studies recently demonstrated the effectiveness of
using a gene-replacement approach to restore cone function in
dog and mouse models of ACHM,11–14 and the neuroprotective
protein ciliary neurotrophic factor also has been shown to
induce a transient restoration of cone function and visually
directed behavior in the CNGB3 dog model.15 Given these
promising results, there are plans to begin human clinical trials
in the near future. This makes the accurate measurement and
stratification of retinal structure and function in ACHM critical,
both in terms of patient selection and subsequent assessment of
treatment response.
Achromatopsia has been classically described as station-
ary1,2,7; however, several recent studies have suggested it is a
progressive condition. Thiadens et al.16 examined 40 ACHM
patients using spectral-domain optical coherence tomography
(SD-OCT), and reported that increased cone cell ‘‘decay’’ and
retinal thinning was correlated with age, and began in early
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childhood. They reported that cone loss, as assessed on SD-
OCT, occurred in 42% (8 of 19) of the achromats aged younger
than 30 years, whereas this finding was observed in 95% (20 of
21) of patients older than 30 years. Thomas et al.17 also noted
in their study (n ¼ 13) that the existence of a hyporeflective
zone (HRZ) and outer nuclear layer (ONL) thinning were both
age dependent. In contrast to these studies, Genead et al18
carried out a variety of investigations to assess macular
structure, including SD-OCT (n ¼ 12), and found that there
was significant structural variability even within individuals of
the same genotype and age. They also found adaptive optics
scanning light ophthalmoscopy (AOSLO) evidence of residual
cone inner segment structure in all but one of the nine patients
assessed, including the oldest patient (55 years), suggesting
that progressive and complete loss of cones in ACHM may not
be inevitable, and was not obviously age-dependent. Sundaram
et al.19 examined 40 ACHM patients aged 6 to 52 years, and
found no correlation between age and visual acuity, total foveal
thickness, foveal ONL thickness, or inner segment ellipsoid
(ISe) intensity and cone loss on SD-OCT.
All of these studies are inherently limited by their cross-
sectional nature, and the debate surrounding whether there is,
or is not, age-dependent cone loss highlights the need for
prospective longitudinal studies of large cohorts of molecularly
proven patients. Thomas et al.20 followed eight patients
longitudinally, over a mean period of 16 months. They reported
that the five younger patients (aged <10 years) demonstrated
progressive disturbance at the foveal photoreceptor inner
segment/outer segment junction on OCT; but the three older
patients (aged >40 years) did not. Due to the small number of
patients, they were not able to perform statistical comparisons
between the two visits.
A further means of assessing macular integrity is through
the use of fundus autofluorescence (FAF),21 which can act as a
surrogate measure of photoreceptor health.22 There are limited
data concerning FAF patterns in ACHM. Michaelides et al.23
reported that the FAF appearance was normal in five affected
members of a GNAT2 family. In a recent study of 10 achromats,
Fahim et al.24 suggested an age-dependent change in FAF, with
younger patients exhibiting increased foveal autofluorescence
(AF), whereas older patients had reduced AF with discrete
borders corresponding to outer retinal defects on SD-OCT.
Greenberg et al.25 also observed FAF abnormalities, including
increased and/or decreased AF (n¼ 17). However, again these
were cross-sectional studies of relatively small size, with no
longitudinal FAF data in ACHM published to date. There is a
need to assess whether FAF signals in ACHM change over time,
which might aid assessment of any progression, genotype
characterization, and potentially serve as a marker for response
to future interventions.
Here we performed serial assessments of visual acuity,
contrast sensitivity, microperimetry (MP), SD-OCT, and FAF, in
the largest longitudinal study of molecularly proven patients to
date, with the goal of providing statistically supported
conclusions regarding the relative frequency and rate of any
observed progression.
METHODS
Subjects
Forty subjects who had been characterized both phenotypi-
cally (including electrophysiologically) and genotypically in a
previously published cross-sectional study19 were prospective-
ly asked to return for follow-up assessment at an interval of
between 12 and 24 months after baseline assessment. The
study protocol adhered to the Tenets of the Declaration of
Helsinki, and was approved by the Moorfields Eye Hospital
Ethics Committee. Informed consent was obtained from all
subjects before entering the study.
Clinical Assessments
A detailed follow-up assessment was undertaken that included
best-corrected visual acuity (BCVA) using an Early Treatment
Diabetic Retinopathy Study chart, contrast sensitivity assess-
ment using the Pelli-Robson chart at 1 m, MP, SD-OCT, and FAF.
All assessments were prospectively standardized to be under-
taken in the same conditions in the follow-up assessment as at
baseline assessment.
Spectral-Domain OCT
After pupillary dilation with tropicamide 1% and phenyleph-
rine 2.5% eye drops, line and volume scans were obtained
using a Spectralis SD-OCT on both eyes (Heidelberg Engineer-
ing, Heidelberg, Germany) using the same protocol as used in
the baseline cross-sectional study.19 Briefly, the volume
acquisition protocol consisted of 49 B-scans (124 lm between
scans; 208 3 208), with Automatic Real Time eye tracking used
whenever possible. During follow-up assessment, the Spec-
tralis SD-OCT was engaged in its follow-up mode, to ensure
that the same scanning location was identified at both time
points. This is achieved by setting the baseline scan as the
reference scan, and the inbuilt software then ensures that the
SD-OCT laser is directed to the same retinal location during
subsequent image acquisition.26 The lateral scale of each image
was estimated using the axial length of the corresponding eye,
obtained from the Zeiss IOL Master (Carl Zeiss Meditec, Jena,
Germany).
Qualitative assessment of foveal morphology was undertak-
en by grading foveal structure on SD-OCT images into one of
five categories: (1) continuous ISe, (2) ISe disruption, (3) ISe
absence, (4) presence of an HRZ, or (5) outer retinal atrophy,
including loss of RPE (Fig. 1). The presence or absence of
foveal hypoplasia was also noted, and was defined as the
persistence of one or more inner retinal layer (outer plexiform
layer, inner nuclear layer, inner plexiform layer, or ganglion cell
layer) through the fovea. Consensus grading was established by
three independent examiners (JA, JCarroll, and MM). Measure-
ments of foveal total retinal thickness (FTRT) (internal limiting
membrane to RPE distance), foveal ONL thickness, and, where
relevant, HRZ diameter, were made by a single observer (JA) at
baseline and follow-up scans, using the digital calipers built
into the software (Heidelberg Eye Explorer; Heidelberg
Engineering), and a 1-pixel:1-lm display with maximal
magnification. In cases of foveal hypoplasia, the distance
between the posterior outer plexiform layer and the external
limiting membrane was taken as the ONL thickness. The mean
of three measurements was used. Due to the optimum image
resolution, imaging speed and follow-up acquisition mode and
eye-tracking used in the Spectralis SD-OCT, retinal thickness
measurements using this device have been shown to be highly
reproducible,26 and this method of assessing foveal thickness
in the assessment of macular pathology has been used
elsewhere.27,28
Fundus Autofluorescence
Fundus autofluorescence was performed at baseline and
follow-up assessments using the AF mode built in to the
Spectralis confocal scanning laser ophthalmoscope (Heidel-
berg Engineering). All images were acquired after mydriasis as
described above, and after the SD-OCT image acquisition
protocol was complete, due to the relatively intense lights used
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FIGURE 1. Longitudinal SD-OCT scans in achromatopsia. Left: Baseline scans indicating genotype, patient number, and age at initial scan. Right:
Follow-up scans indicating patient number and interval between baseline and follow-up scans in months. Center: Foveal magnification (33) of
corresponding scan (gray arrows). Shown are the left eyes of a typical subject from each of the five SD-OCT categories, all of whom demonstrated
no change in SD-OCT structure over the study period (from the top row down: patient 35 with a continuous ISe band at both time points; patient 21
with a disrupted ISe layer at both time points; patient 11 with an absent ISe layer at both time points; patient 12 with an HRZ at both time points;
and patient 30 with outer retinal atrophy at both time points). Nonmagnified images represent 4500 lm horizontally and 1000 lm vertically; image
scaling has been corrected for axial length. Scale bar: 200 lm.
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during FAF acquisition and the photophobic nature of
achromats. Images were acquired using a 308 field, with an
optically pumped solid-state laser producing an excitation
wavelength of 488 nm. The induced AF was detected through a
barrier filter of 500 nm, and acquired after focusing the retinal
image using the 820-nm infrared mode and sensitivity
adjustment at 488 nm.
In the case of patients who had areas of abnormally reduced
AF signal, measurements of this area were performed by
describing this region with a mouse-driven cursor, and
recording the area given by the in-built image analysis software
(Heidelberg Eye Explorer; Heidelberg Engineering); this
method has been used in the assessment of progressive
macular disease elsewhere.29,30 All FAF measurements were
made by a single observer (JA), and for each FAF image, the
mean of three area measurements was calculated and used for
further analysis.
Microperimetry
Microperimetry (MP) was performed in all subjects on both
eyes, and after pupillary dilation, in a darkened room using the
MP1 microperimeter (Nidek Technologies, Padova, Italy) in
follow-up mode, and otherwise using the same testing
conditions as at baseline assessment.19 Two tests were
undertaken on each eye, using a customized test grid of 44
retinal locations situated within an 88 radius to cover the
macular and paramacular region, and over which the mean
retinal sensitivity was recorded. During each test, the non-
tested contralateral eye was occluded.
Background illuminance was set within the mesopic range
(1.27 cd/m2), and patients maintained fixation by looking at a
28 target. A variable intensity Goldmann size III (4 mm2)
stimulus of 200-ms duration was used as the testing stimulus. A
4-2 testing strategy was used, with the intensity of the stimulus
reduced in 4-dB steps until the patient no longer detected it.
The stimulus intensity then increased in 2-dB steps until
detected once again. Projection of the stimulus into the blind
spot at 30-second intervals tested for false-positive errors.
Fixation stability was assessed using the bivariate contour
ellipse area (BCEA) analysis, which represents an area in
degrees where 68% (i.e., 1 SD) of fixation points are located31;
this value is reported by the Nidek software. An active eye-
tracking system ensured accurate stimulus projection in
relation to retinal landmarks to correct for fixation errors.
Data Analysis Methods
Histogram plots were used to verify the normality of data
before the use of any parametric tests. Statistical analyses were
performed using GraphPad Prism, version 5 (GraphPad
Software, Inc., La Jolla, CA, USA). As the left eye had been
selected for further analysis in the original cross-sectional study
(which had found no significant difference in measured
parameters between eyes),19 this eye also underwent detailed
further analysis in the follow-up study. Patient identification
numbers were kept the same as in the cross-sectional study for
ease of reference. Variability indicators (6) represent 1 SD in
normally distributed metrics.
RESULTS
Thirty-eight (95%) of the 40 patients who were assessed at
baseline were able to attend for follow-up assessment within
the 12- to 24-month study recall window. Two female patients
were unable to return; one due to the onset of unrelated long-
term illness (patient 25) and the other due to pregnancy
(patient 32). Of the 38 patients who were followed up, 20
were male (53%) and 18 were female (47%). The mean age of
the follow-up cohort was 25 years at baseline (612.5; range, 6–
52 years), with a mean follow-up interval of 19.5 months (62.8
months; range, 13–24 months). The Table summarizes the
clinical findings, and includes age at baseline, interval of
follow-up period, genotype, and functional and structural
parameters over time.
Best Corrected Visual Acuity and Contrast
Sensitivity
The mean BCVA at baseline was 0.92 logMAR (60.13; range,
0.74–1.32 logMAR), and was not significantly different from
the mean BCVA at follow-up, which also measured 0.92
logMAR (60.11; range, 0.74–1.28 logMAR) (paired t-test; P ¼
0.89). The mean of the logarithm of the contrast sensitivity
(logCS) at baseline of 1.16 logCS (60.23; range, 0.5–1.55
logCS) was also not significantly different from that measured
at follow-up of 1.21 logCS (60.32; range, 0.25–1.65 logCS)
(paired t-test; P ¼ 0.22); where higher logCS values indicate
better contrast sensitivity.
Spectral-Domain OCT
In 37 of the 38 patients who underwent serial SD-OCT, foveal
scans were acquired at baseline and follow-up that were
comparable across time points. In one patient (patient 1)
foveal follow-up SD-OCT images could not be obtained due to
poor fixation, and this patient was excluded from further SD-
OCT analysis. Two (5%) of these 37 patients demonstrated
progression on SD-OCT between time points: patient 2 (10
years old at first visit) progressed from category 1 (continuous
ISe layer) at baseline to category 2 (ISe disruption) over a 20-
month period, and patient 31 (33 years old at first visit)
progressed from category 2 (ISe disruption) to category 4
(HRZ) over the same number of months (Fig. 2). However,
these observed changes were subtle in patient 2, and the SD-
OCT findings of patient 31 at baseline, with the high
reflectivity foveal lesion, are not typically seen in ACHM. No
other patients showed evidence of progression, either in terms
of transition to another SD-OCT category or progression within
a category (Fig. 1).
The right eye SD-OCT images of all patients were also
graded at baseline and follow-up assessment, given that in the
cross-sectional study no parameter measured demonstrated
any significant difference between eyes,19 and so presumably
any change over time observed in both eyes would more
likely represent real disease progression. Both patients with
SD-OCT evidence of progression in the left eye showed similar
deterioration in the right eye (Fig. 2), whereas the remaining
patients had the same SD-OCT appearance in the right eye at
baseline and follow-up, as was the case for their left eyes. The
changes in patient 2 were again subtle in the right eye, but
that the SD-OCT changes were mirrored in both eyes in both
patients 2 and 31 would lend support to the view that the
morphological change detected in these two patients was
real.
The remaining 35 patients (95%) showed no evidence of
deterioration in SD-OCT appearance on qualitative assessment
(Fig. 1). No patients had a change in the presence or absence of
foveal hypoplasia between baseline and follow-up assessment.
Foveal Total Retinal Thickness, ONL Thickness,
and HRZ Diameter
Foveal total retinal thickness was measured in all 37 patients
who had serial foveal SD-OCT assessments. There was no
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statistically significant change between visits (i.e., follow-up
thickness minus baseline thickness; negative numbers indicat-
ing thinning over time) in FTRT in the cohort, with mean
change of0.1 lm (95% confidence interval (CI)1.3 toþ1.1
lm; range, 9 toþ4 lm) (paired t-test; P ¼ 0.83) (Table).
Three (8%) of the 37 patients who underwent serial foveal
SD-OCT scanning (patients 10, 28, and 30) did not have a
structurally-distinct ONL layer that could be accurately
measured, and so were excluded from the ONL thickness
analysis. The mean ONL thickness change in the remaining 34
FIGURE 2. The left and right eye scans of the two achromatopsia subjects who demonstrated a change in SD-OCT appearance over the time course
of the study. Layout is as in Figure 1. Top two rows: Patient 2 showed a continuous ISe layer at the fovea at initial scan in both the OS and OD eyes,
and subsequently a disrupted ISe layer in both eyes at follow-up scan 20 months later (black arrows). Bottom two rows: Patient 31 showed a
disrupted ISe layer at initial scan in both eyes and an HRZ 20 months later (black arrows). Nonmagnified images represent 4500 lm horizontally and
1000 lm vertically; image scaling has been corrected for axial length. Scale bar: 200 lm.
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patients of0.6 lm (95% CI1.7 toþ0.5 lm; range,10 toþ3
lm) was not statistically significant between assessments
(paired t-test; P ¼ 0.27) (Table). Only one patient had ONL
thinning of 10 lm or more (patient 2 with 10 lm), which is in
keeping with the qualitative deterioration of outer retinal
structure on SD-OCT observed in this patient. In the nine
patients who had an HRZ at both time point assessments, there
was no statistically significant change in the diameter of the
HRZ over a mean follow-up time of 19.6 months in this group
(paired t-test; P ¼ 0.42).
Microperimetry
All 38 patients underwent follow-up MP testing on two or more
occasions, and the mean of these tests was used for subsequent
analysis. The mean retinal sensitivity of this cohort at baseline
was 16.6 dB (63.4; range, 3.1–19.9 dB), and was not
significantly different from that measured at follow-up (16.5
dB 63.07; range, 5.8–16.5 dB) (paired t-test; P¼ 0.84) (Table).
The fixation stability measured at baseline (median ¼ 9.18;
range, 1.7–658) was also not significantly different from that at
follow-up (median ¼ 8.28; range, 1.7–61.88) (Wilcoxon
matched-pairs signed rank test; P ¼ 0.58) (Table). At baseline
assessment, six subjects had a scotoma (defined as 0 dB
sensitivity in ‡1 retinal location). Follow-up MP assessment
also showed that the same six patients had scotomas. In
addition, one further patient (patient 5, 17 years old at baseline
assessment) developed a scotoma that was not apparent on
initial testing, and was evident in both follow-up MP tests 16
months later (Fig. 3). However, the change in point sensitivity
is small and would fall within intertest variability limits, as can
be seen in the variation in sensitivities in the points around
those that developed an absolute scotoma.
Fundus Autofluorescence
In 30 (84%) of the 38 patients, baseline and follow-up FAF
images were of sufficient quality to enable accurate classifica-
tion and, where necessary, measurement of the area of reduced
FAF signal. Several patients experienced discomfort with the
bright light needed to acquire FAF images, and given their
extreme photophobia, this contributed to relatively lower
patient concordance and successful acquisition compared with
other serial assessment modalities. We observed three FAF
patterns at baseline (n¼ 30): (1) a normal FAF pattern, seen in
11 patients (37%); (2) an abnormal central increase in FAF, seen
in 4 patients (13%); and (3) a discretely bordered abnormal
central reduction in FAF, seen in 15 patients (50%) (Fig. 4). No
change in the type of FAF pattern was observed between
baseline and follow-up assessments, or between eyes, in any of
the patients.
Given that the reduced FAF pattern had well-demarcated
borders amenable to quantification, the area of reduced FAF
was measured at baseline and follow-up in the 15 patients with
this FAF phenotype. There was a small but statistically
significant increase in median area of reduced FAF between
assessments (Wilcoxon matched-pairs test; P¼0.002), with the
median change beingþ0.03 mm2 (interquartile range, þ0.01 to
þ0.13 mm2; range, 0 to þ0.28 mm2), where positive numbers
indicate an increase in the area of reduced FAF signal over the
mean follow-up time in this subgroup of 19.3 months.
The mean age of patients in the group with a normal FAF
appearance was 27.6 years (range, 10–52 years), 16.0 years
(range, 11–29 years) in the group with an increased FAF
pattern, and 29.3 years (range, 11–49 years) in the group with
a reduced FAF pattern. There was no statistically significant
difference in the ages among the three FAF pattern groups
(Kruskal Wallis test; P < 0.05). In one of the two patients in
whom we detected evidence of progressive change on SD-OCT
FIGURE 3. The microperimetry findings in patient 5, who developed a scotoma during this study. (A) Microperimetry findings at baseline. Numbers
indicate retinal sensitivity (dB) at that location. (B) Microperimetry findings 16 months later indicate an absolute scotoma at two locations.
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FIGURE 4. Longitudinal FAF in achromatopsia, demonstrating the three patterns observed (patient number, genotype, and age at baseline
acquisition indicated at left; patient number and follow-up interval in months indicated at right). Top: Pattern 1: reduced FAF signal centrally with a
well-demarcated border.Middle: Pattern 2: normal FAF appearance. Bottom: Pattern 3: a central increase in FAF. These patterns were not statistically
significantly age dependent. All of the three above patients harbor CNGA3 disease-causing alleles and are of a similar age, which serves to highlight
both the wide phenotypic variation seen in achromatopsia even within the same genotype, and also the lack of strict age-dependency.
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(patient 31), there was only a minimal increase in the area of
reduced FAF ofþ0.01 mm2 over a follow-up time of 20 months;
the other patient who progressed on SD-OCT (patient 2) had a
normal FAF pattern at both time points.
We observed a statistically significant correlation between
more disordered SD-OCT structure (category 1 to 5) and a
more abnormal FAF pattern (graded from normal through
central increased FAF to central decreased FAF) (Spearman r¼
0.55; P ¼ 0.002).
Genotype–Phenotype Correlation
Of the two patients who progressed on qualitative SD-OCT
assessment, one had disease-causing variants in CNGA3, and
the other in CNGB3, suggesting no significant association of
progression in CNGA3 versus CNGB3. This would also be in
agreement with our previous findings that there was no
association between severity of SD-OCT phenotype or pres-
ence of foveal hypoplasia, and genotype.19 However, with only
two patients appearing to show progression on SD-OCT, the
numbers of progressors by genotype are too small to be
anything other than suggestive.
When we analyzed the CNGA3 and CNGB3 groups
separately, we again did not find any statistically significant
difference between the baseline and follow-up measures in
BCVA (Wilcoxon matched-pairs test; CNGA3 P¼ 0.75; CNGB3
P ¼ 0.72), contrast sensitivity (CNGA3 P ¼ 0.06; CNGB3 P ¼
0.11), MP mean sensitivity (CNGA3 P¼ 0.33; CNGB3 P¼ 1.0)
or MP mean BCEA (CNGA3 P ¼ 1.0; CNGB3 P ¼ 0.41). There
was also no statistically significant difference between the
CNGA3 and CNGB3 groups in the change in FTRT or ONL
thickness (FTRT: Mann-Whitney U test; P ¼ 0.33; ONL
thickness: unpaired t-test; P ¼ 0.58).
In the case of the CNGA3 and CNGB3 patients, there was
no significant association between the numbers of patients
exhibiting each of the three observed FAF patterns and their
genotype (v2 test; P ¼ 0.40).
DISCUSSION
This study is, to the best of our knowledge (PubMed search June
2, 2014; keywords: achromatopsia, rod monochromatism), the
largest prospective longitudinal study of ACHM with the longest
mean follow-up time of 19.5 months, and sufficient patient
numbers for statistical analysis looking for change over time.
Our cohort did not show any evidence of a statistically
significant change over time in BCVA, contrast sensitivity, or
MP measures of retinal sensitivity and fixation stability, either
as whole, or as separate CNGA3 and CNGB3 genotype
subgroups. Only 2 (5%) of 37 patients followed up longitudi-
nally demonstrated evidence of progressive outer retinal
changes according to independently graded qualitative SD-
OCT analysis over the follow-up period. Thirty-five patients
(95%) demonstrated no qualitative changes on their SD-OCT
images between baseline and follow-up assessment. This
agrees with our longitudinal quantitative assessment of both
TRFT and ONL thickness, both of which showed no statistically
significant change in the cohort over the time course of this
study. Neither of the two patients (2 and 31) who had a
qualitative change in SD-OCT had any significant deterioration
over time in their BCVA, contrast sensitivity, MP mean
sensitivity, or MP mean BCEA. It has been shown in other
inherited retinal conditions that SD-OCT changes may precede
deterioration of clinical assessment parameters, such as
BCVA32 and FAF,33 and so despite a failure to demonstrate
deterioration in other clinical measures used in this study, the
SD-OCT changes in these two patients likely represent real
change. Serial assessment using other sensitive retinal imaging
techniques, such as AOSLO, may shed further light on the
earliest indicators of any progression in ACHM.
We saw no patients with an ONL or central macular
thickness (CMT) thinning of more than 10 lm, which contrasts
with Thomas et al.,20 who report that the five pediatric
patients in their study (aged <10 years at first visit) showed SD-
OCT evidence of thinning of both CMT and ONL over a mean
follow-up time of 13 months. Three of these five children
appear to have had an ONL thinning of more than 10 lm,
although the numerical values are not stated. The three adults
in their study (aged >40 years) showed only minimal variation
in these parameters over a mean follow-up of 20 months, in
keeping with our study. However, in at least two of the
children, the evidence for progression was not unequivocal.
Thomas et al.20 described how patients 1 and 2 had developed
an outer retinal hyperreflective zone, which they interpreted
as an indication of progression. It should be noted, however,
that the same two patients had a generalized increase in
reflectivity of several other layers in their respective follow-up
OCT images, including the nerve fiber layer and ganglion cell
layer, and so the possibility that this apparent increase in outer
retinal reflectivity over time may be artifactual remains.
Furthermore, they were unable to perform any statistical
analyses due to their small sample size. The reason for the
difference in our respective findings regarding the evidence for
progressive thinning of the ONL and/or CMT may be related to
the fact that we had only three children aged 10 years or
younger at first visit. However, our cohort did contain a total of
eight children aged 12 years or younger at first visit, and the
much larger number of patients in our cohort and the
consequent ability to carry out a statistical analysis would lend
further support to our findings. We also observed no
statistically significant change in the diameter of the HRZ in
the nine patients in our study who had this finding at both time
point assessments.
Fundus Autofluorescence
Our findings of three distinct FAF patterns is in broad
agreement with those of Fahim et al.24 We also found a very
small but statistically significant increase in the area of reduced
FAF over time among patients who displayed that pattern,
indicating that serial FAF may play a role in assessing change in
ACHM. There was no statistically significant difference
between ages in the three FAF patterns. However, no patients
changed their FAF pattern during the time-course of this study,
and the rate of increase in the size of reduced FAF was very
slow (median 0.02 mm2/y); by comparison, FAF atrophy rates
in AMD are several orders of magnitude greater, in the realm of
several mm2 per year.29 In addition, there were three patients
aged 13 years or younger in the group that had a normal FAF
pattern, and one young patent (11 years old) who had a
reduced FAF pattern. This again is in keeping with a highly
variable disease, where age and genotype are insufficient
predictors of phenotype (Fig. 4). However, caution needs to be
exercised in overinterpreting these data and no definitive
conclusions can be reached without larger cohorts.
We also observed a moderately strong correlation between
degree of foveal SD-OCT structural disorganization and degree
of FAF abnormality. Fundus autofluorescence intensity may
plausibly progress in sequence, from normal signal through
increased FAF signal to subsequent FAF signal reduction. It is
also possible that the five SD-OCT categories represent a
sequence in the severity of foveal outer retinal structure
disorganization (from a continuous ISe to outer retinal
atrophy), thereby suggesting that the observed correlation of
SD-OCT outer retinal architecture to FAF pattern may be of
prognostic value, in addition to potentially acting as a further
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possible metric in treatment trials. Longer follow-up with larger
molecularly confirmed cohorts, combined with more quanti-
tative assessment of FAF, are required to establish whether SD-
OCT structural abnormality precedes or follows FAF abnor-
malities in ACHM.
The diagnostic and prognostic relevance of FAF in ACHM
has yet to be established. Robson et al.34 demonstrated that
increased FAF in cone or cone-rod dystrophy is associated with
reduced rod and cone sensitivity, with scotopic sensitivity
reductions being milder than photopic losses. In contrast, in
AMD, increased FAF may be more indicative of rod as opposed
to cone dysfunction.35 We found that the MP mean retinal
sensitivity (averaged between the two assessments at each time
point) was significantly higher in the increased FAF group
(median 18.71 dB) compared with the decreased FAF group
(median 17.33 dB) (Mann-Whitney U test; P ¼ 0.008), but did
not find any statistically significant difference in retinal
sensitivity between normal FAF and increased FAF groups
(Mann-Whitney U test; P ¼ 0.19). In terms of monitoring for
progressive change, it would seem that this measure, like the
others we have investigated, would need to be assessed over a
greater time span, given the likely slow rate of change. This
factor, along with the significant degree of patient variability
observed, also highlights the need to consider patients on an
individual basis in terms of potential suitability for interven-
tion. The use of further quantitative FAF analyses24,35,36 may
increase the sensitivity of FAF assessment in ACHM, but it is
still likely that any progression by this measure will occur at a
very slow rate in a subset of patients.
Age-Dependency of Progression
In their retrospective study, Thiadens et al.37 reported that,
over a mean follow-up of 15 years, 12% of the ACHM patients
they reviewed had a deterioration in BCVA; in contrast with
other cross-sectional studies that have not found an age-
dependent deterioration in BCVA.16,17,19 In their longitudinal
study of eight patients, Thomas et al.20 also showed no
evidence of a decrease in BCVA over the mean follow-up of 18
months. Khan et al.3 also reported that 6 to 12 years had
elapsed between their detecting and subsequently failing to
detect photopic ERG response in two affected adult CNGB3
individuals. Given the aforementioned time spans, it is likely
that any progression in this condition is very slow and possibly
subtle; it may be that to see clear evidence of progression in
more patients, longitudinal studies of a much longer time
course that may extend into many years or even decades would
be required.
There is also significant phenotypic variation among
individuals in terms of the existence and time course of any
such progression. This phenotypic variability is illustrated in
the findings of OCT studies16,19,38–40 and AOSLO studies.18,41,42
Such variation may confound attempts to look for progression
en bloc in what is likely to be a more heterogeneous condition
than previously thought. Our data suggest that each individual
patient’s phenotype, and the significance and time course of
any progression, does not correlate with genotype and is highly
variable among individuals. Probing this more deeply may
require more detailed longitudinal cellular phenotyping with
ultrastructural assessments such as AOSLO, potentially in
concert with AO-guided psychophysical assessments. The
need for such deep-phenotyping has clear implications for
the selection and monitoring of patients for anticipated
therapeutic interventions. For most of the retinal parameters
measured, our initial cross-sectional study did not find any
association with CNGA3 or CNGB3 genotype.19 However, we
did observe that retinal sensitivity was significantly higher in
the CNGB3 group. This longitudinal study did not identify any
measured parameters that worsened significantly between
time points when each genotype group was analyzed alone.
The longitudinal findings herein broadly agree with our
initial cross-sectional study that age and genotype are not
necessarily the critical factors in selecting patients for gene
therapy. The vast majority of parameters assessed in this study
did not change over time, and those that did, either did so very
slowly, or in a very small proportion of patients. This supports
the view that the potential treatment window for gene therapy
may not only be wider in terms of age than has been previously
suggested, but that it may remain open for a longer period. Our
data also lend support to the view that ACHM is heteroge-
neous, and that factors other than age and genotype are likely
to influence the phenotype. Such factors may have an as-of-yet
unknown influence on any planned therapeutic interventions.
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Serial assessment of achromatopsia using multiple imaging and
functional modalities reveals limited and slow rates of
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progression, the implications of which are discussed in the
context of imminent clinical gene therapy trials.
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